[Ip-health] NEJM paper on extending exclusivity

[Benjamin Krohmal]

--
[ Picked text/plain from multipart/alternative ]
The August 10th New England Journal of Medicine featured a paper by
Alastair Wood proposing radical changes in the American drug-approval
process.  Like CPTech and others, Wood proposes changing the current
system to reward meaningful pharmaceutical innovations more than "me
too" drugs.  Unlike CPTech, Wood proposes to accomplish this by offer
longer terms of patent exclusivity for more clinically valuable drugs.

According to Wood, "increased clinical value should be reflected in
increased commercial value through a longer period of exclusivity."

The full article is available here:
http://content.nejm.org/cgi/content/full/355/6/618





Benjamin Krohmal
Research Associate
Consumer Project on Technology
Tel: +1-202-332-2670 ex. 14
Fax: +1-202-332-2673
ben.krohmal@cptech.org